The identification of BRP, an anti-obesity peptide, showcases the transformative role of AI in drug discovery and its ...

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new ...

Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

Moderation has resulted in consumers across different age demographics to be more interested non-alcohol beer as the segment ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Canada Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with ...

Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web ...